
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx is a leader in the transplant testing market and has shown strong financial performance in recent quarters. The company has a strong management team, has successfully navigated regulatory changes, and is expanding into new markets and product offerings. With a positive outlook for the future, CareDx is poised for continued growth and potentially increased revenue and profitability.
Bears say
CareDx is heavily dependent on its AlloSure Kidney and AlloMap Heart tests for revenue, and it must generate sufficient revenue and reimbursement from these offerings to meet its expectations. However, competition and rapid changes in the diagnostic testing field could pose challenges for CDNA. Clinicians and healthcare administrators may be slow to adopt new products, potentially hindering CDNA's growth and market penetration. Furthermore, the recent draft LCD proposed lower test interval limits for kidney, heart, and lung testing, which would significantly cut CDNA's total addressable market. While the final LCD set more favorable limits, risks remain for reimbursement and pricing in the transplant and oncology markets. In addition, the company's reliance on acquisitions for growth may have an impact on its stock price.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares